Loading...

CompuGroup Medical Societas Europaea

DB:COP
Snowflake Description

Solid track record with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
COP
DB
€3B
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

CompuGroup Medical Societas Europaea develops and sells software and information technology services for healthcare sector worldwide. The last earnings update was 74 days ago. More info.


Add to Portfolio Compare Print
  • CompuGroup Medical Societas Europaea has significant price volatility in the past 3 months.
COP Share Price and Events
7 Day Returns
4.2%
DB:COP
-0.2%
DE Healthcare Services
-1.1%
DE Market
1 Year Returns
55.5%
DB:COP
43.2%
DE Healthcare Services
-8.5%
DE Market
COP Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
CompuGroup Medical Societas Europaea (COP) 4.2% 6.9% 33.1% 55.5% 88% 273.4%
DE Healthcare Services -0.2% 3.2% 29.4% 43.2% 78.4% 220.4%
DE Market -1.1% -0.4% -4% -8.5% 8.1% 9.4%
1 Year Return vs Industry and Market
  • COP outperformed the Healthcare Services industry which returned 43.2% over the past year.
  • COP outperformed the Market in Germany which returned -8.5% over the past year.
Price Volatility
COP
Industry
5yr Volatility vs Market

Value

 Is CompuGroup Medical Societas Europaea undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of CompuGroup Medical Societas Europaea to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for CompuGroup Medical Societas Europaea.

DB:COP Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 8 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:COP
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Healthcare Services Unlevered Beta Simply Wall St/ S&P Global 1.08
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.082 (1 + (1- 30%) (10.6%))
1.109
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.11
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.109 * 5.96%)
6.84%

Discounted Cash Flow Calculation for DB:COP using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for CompuGroup Medical Societas Europaea is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:COP DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 6.84%)
2020 102.27 Analyst x7 95.73
2021 109.52 Analyst x6 95.95
2022 110.61 Est @ 1% 90.71
2023 111.46 Est @ 0.77% 85.55
2024 112.13 Est @ 0.61% 80.56
2025 112.68 Est @ 0.49% 75.78
2026 113.15 Est @ 0.41% 71.22
2027 113.55 Est @ 0.36% 66.91
2028 113.91 Est @ 0.32% 62.82
2029 114.25 Est @ 0.29% 58.98
Present value of next 10 years cash flows €784.22
DB:COP DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= €114.25 × (1 + 0.23%) ÷ (6.84% – 0.23%)
€1,732.92
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €1,732.92 ÷ (1 + 6.84%)10
€894.56
DB:COP Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €784.22 + €894.56
€1,678.78
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €1,678.78 / 48.83
€34.38
DB:COP Discount to Share Price
Calculation Result
Value per share (EUR) From above. €34.38
Current discount Discount to share price of €73.25
= -1 x (€73.25 - €34.38) / €34.38
-113.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of CompuGroup Medical Societas Europaea is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for CompuGroup Medical Societas Europaea's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are CompuGroup Medical Societas Europaea's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:COP PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in EUR €2.02
DB:COP Share Price ** DB (2019-07-19) in EUR €73.25
Germany Healthcare Services Industry PE Ratio Median Figure of 6 Publicly-Listed Healthcare Services Companies 21.4x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.67x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of CompuGroup Medical Societas Europaea.

DB:COP PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= DB:COP Share Price ÷ EPS (both in EUR)

= 73.25 ÷ 2.02

36.24x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • CompuGroup Medical Societas Europaea is overvalued based on earnings compared to the DE Healthcare Services industry average.
  • CompuGroup Medical Societas Europaea is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does CompuGroup Medical Societas Europaea's expected growth come at a high price?
Raw Data
DB:COP PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 36.24x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts
6.6%per year
Europe Healthcare Services Industry PEG Ratio Median Figure of 11 Publicly-Listed Healthcare Services Companies 1.85x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.44x

*Line of best fit is calculated by linear regression .

DB:COP PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 36.24x ÷ 6.6%

5.5x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • CompuGroup Medical Societas Europaea is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on CompuGroup Medical Societas Europaea's assets?
Raw Data
DB:COP PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in EUR €5.69
DB:COP Share Price * DB (2019-07-19) in EUR €73.25
Germany Healthcare Services Industry PB Ratio Median Figure of 7 Publicly-Listed Healthcare Services Companies 2.04x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.73x
DB:COP PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= DB:COP Share Price ÷ Book Value per Share (both in EUR)

= 73.25 ÷ 5.69

12.87x

* Primary Listing of CompuGroup Medical Societas Europaea.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • CompuGroup Medical Societas Europaea is overvalued based on assets compared to the DE Healthcare Services industry average.
X
Value checks
We assess CompuGroup Medical Societas Europaea's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check)
  5. CompuGroup Medical Societas Europaea has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is CompuGroup Medical Societas Europaea expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
6.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is CompuGroup Medical Societas Europaea expected to grow at an attractive rate?
  • CompuGroup Medical Societas Europaea's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • CompuGroup Medical Societas Europaea's earnings growth is positive but not above the Germany market average.
  • CompuGroup Medical Societas Europaea's revenue growth is positive but not above the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:COP Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:COP Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts 6.6%
DB:COP Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 8 Analysts 3.2%
Germany Healthcare Services Industry Earnings Growth Rate Market Cap Weighted Average 7.7%
Europe Healthcare Services Industry Revenue Growth Rate Market Cap Weighted Average 6.4%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:COP Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:COP Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 872 137 2
2022-12-31 803 125 3
2021-12-31 756 148 101 7
2020-12-31 748 141 96 8
2019-12-31 736 144 96 8
DB:COP Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-03-31 747 155 99
2018-12-31 736 136 92
2018-09-30 707 112 64
2018-06-30 678 109 49
2018-03-31 624 101 36
2017-12-31 599 86 31
2017-09-30 586 89 41
2017-06-30 583 80 46
2017-03-31 578 78 47
2016-12-31 571 68 45
2016-09-30 562 67 41
2016-06-30 553 68 36

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • CompuGroup Medical Societas Europaea's earnings are expected to grow by 6.6% yearly, however this is not considered high growth (20% yearly).
  • CompuGroup Medical Societas Europaea's revenue is expected to grow by 3.2% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:COP Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below

All data from CompuGroup Medical Societas Europaea Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:COP Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 2.81 2.81 2.81 1.00
2022-12-31 2.57 2.57 2.57 1.00
2021-12-31 2.07 2.33 1.69 7.00
2020-12-31 2.01 2.37 1.62 8.00
2019-12-31 1.93 2.10 1.78 5.00
DB:COP Past Financials Data
Date (Data in EUR Millions) EPS *
2019-03-31 2.02
2018-12-31 1.88
2018-09-30 1.28
2018-06-30 1.01
2018-03-31 0.72
2017-12-31 0.63
2017-09-30 0.82
2017-06-30 0.92
2017-03-31 0.95
2016-12-31 0.90
2016-09-30 0.82
2016-06-30 0.72

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • CompuGroup Medical Societas Europaea is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess CompuGroup Medical Societas Europaea's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
CompuGroup Medical Societas Europaea has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has CompuGroup Medical Societas Europaea performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare CompuGroup Medical Societas Europaea's growth in the last year to its industry (Healthcare Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • CompuGroup Medical Societas Europaea has delivered over 20% year on year earnings growth in the past 5 years.
  • CompuGroup Medical Societas Europaea's 1-year earnings growth exceeds its 5-year average (177.1% vs 22.8%)
  • CompuGroup Medical Societas Europaea's earnings growth has exceeded the DE Healthcare Services industry average in the past year (177.1% vs 106.7%).
Earnings and Revenue History
CompuGroup Medical Societas Europaea's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from CompuGroup Medical Societas Europaea Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:COP Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 746.63 99.02 18.76
2018-12-31 735.65 92.34 18.76
2018-09-30 706.63 63.61 20.74
2018-06-30 678.05 49.26 20.74
2018-03-31 624.32 35.73 20.74
2017-12-31 599.44 31.31 20.74
2017-09-30 586.17 40.81 16.04
2017-06-30 583.22 46.29 16.04
2017-03-31 578.04 47.20 16.04
2016-12-31 570.94 44.53 16.04
2016-09-30 561.73 40.59 15.70
2016-06-30 553.06 35.95 15.70
2016-03-31 556.11 27.39 15.70
2015-12-31 553.35 38.49 15.70
2015-09-30 548.37 33.64 14.78
2015-06-30 547.47 39.51 14.78
2015-03-31 534.98 42.06 14.78
2014-12-31 524.99 26.02 14.78
2014-09-30 510.86 28.94 13.94
2014-06-30 495.90 23.61 13.94
2014-03-31 479.22 18.25 13.94
2013-12-31 469.96 23.60 13.94
2013-09-30 462.50 19.35 14.29
2013-06-30 457.52 20.03 14.29
2013-03-31 458.96 32.25 14.29
2012-12-31 457.67 30.72 14.29
2012-09-30 453.47 33.46 11.20

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Whilst CompuGroup Medical Societas Europaea has efficiently used shareholders’ funds last year (Return on Equity greater than 20%), this is metric is skewed due to its high level of debt.
  • CompuGroup Medical Societas Europaea used its assets more efficiently than the DE Healthcare Services industry average last year based on Return on Assets.
  • CompuGroup Medical Societas Europaea has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess CompuGroup Medical Societas Europaea's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
CompuGroup Medical Societas Europaea has a total score of 5/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is CompuGroup Medical Societas Europaea's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up CompuGroup Medical Societas Europaea's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • CompuGroup Medical Societas Europaea's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • CompuGroup Medical Societas Europaea's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of CompuGroup Medical Societas Europaea's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from CompuGroup Medical Societas Europaea Company Filings, last reported 3 months ago.

DB:COP Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 280.14 329.57 44.29
2018-12-31 273.00 329.67 25.88
2018-09-30 250.06 331.06 35.02
2018-06-30 245.42 327.83 34.83
2018-03-31 234.27 320.86 36.41
2017-12-31 236.06 365.68 30.59
2017-09-30 235.13 353.02 28.90
2017-06-30 224.56 364.60 31.15
2017-03-31 232.06 352.37 35.80
2016-12-31 218.65 373.24 28.35
2016-09-30 205.76 370.95 30.21
2016-06-30 196.10 371.44 28.41
2016-03-31 203.96 354.24 30.55
2015-12-31 192.61 370.49 25.81
2015-09-30 188.71 374.88 29.14
2015-06-30 184.11 372.37 23.31
2015-03-31 194.68 351.42 27.80
2014-12-31 175.63 367.66 23.05
2014-09-30 193.45 360.47 28.75
2014-06-30 179.71 333.84 15.50
2014-03-31 188.83 323.99 29.73
2013-12-31 184.67 329.61 25.84
2013-09-30 178.17 297.92 22.61
2013-06-30 173.01 265.48 19.18
2013-03-31 192.01 241.46 20.34
2012-12-31 179.41 282.69 21.95
2012-09-30 180.93 261.16 22.05
  • CompuGroup Medical Societas Europaea's level of debt (117.6%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (171.7% vs 117.6% today).
  • Debt is well covered by operating cash flow (46.9%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 23.7x coverage).
X
Financial health checks
We assess CompuGroup Medical Societas Europaea's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. CompuGroup Medical Societas Europaea has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is CompuGroup Medical Societas Europaea's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.68%
Current annual income from CompuGroup Medical Societas Europaea dividends. Estimated to be 0.78% next year.
If you bought €2,000 of CompuGroup Medical Societas Europaea shares you are expected to receive €14 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • CompuGroup Medical Societas Europaea's pays a lower dividend yield than the bottom 25% of dividend payers in Germany (1.49%).
  • CompuGroup Medical Societas Europaea's dividend is below the markets top 25% of dividend payers in Germany (3.92%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:COP Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
Europe Healthcare Services Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 1.5%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3.2%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:COP Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2023-12-31 0.50 1.00
2022-12-31 0.50 2.00
2021-12-31 0.62 7.00
2020-12-31 0.60 8.00
2019-12-31 0.53 8.00
DB:COP Past Annualized Dividends Data
Date (Data in €) Dividend per share (annual) Avg. Yield (%)
2019-04-01 0.500 0.802
2018-05-17 0.350 0.757
2017-03-31 0.350 0.723
2016-03-31 0.350 0.916
2015-05-20 0.350 1.118
2014-03-27 0.350 1.684
2013-04-02 0.350 1.928
2012-08-09 0.250 1.716
2012-03-29 0.250 2.252
2011-03-03 0.250 2.691
2010-08-12 0.250 2.583
2010-03-05 0.250 3.016

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • CompuGroup Medical Societas Europaea is not paying a notable dividend for Germany, therefore no need to check if the payments are stable.
  • CompuGroup Medical Societas Europaea is not paying a notable dividend for Germany, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of CompuGroup Medical Societas Europaea's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of CompuGroup Medical Societas Europaea's dividends as it is not paying a notable one for Germany.
Future Payout to shareholders
  • No need to calculate the sustainability of CompuGroup Medical Societas Europaea's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess CompuGroup Medical Societas Europaea's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can CompuGroup Medical Societas Europaea afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. CompuGroup Medical Societas Europaea has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of CompuGroup Medical Societas Europaea's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Frank Gotthardt
COMPENSATION €4,193,700
AGE 69
TENURE AS CEO 11 years
CEO Bio

Mr. Frank Gotthardt has been the Chairman of Management Board and Chief Executive Officer of CompuGroup Medical Societas Europaea (formerly, CompuGroup Holding AG) since July 1, 2008. He has been Chairman of the Supervisory Board of Rhein Massiv Verwaltung AG, CompuGroup Medical Deutschland AG and Member of the Supervisory Board of XLHEALTH AG. Mr. Gotthardt serves as the Chairman and Chief Executive Officer of Compugroup Medical AG. Mr. Gotthardt became a pioneer of IT in the healthcare sector in his days as a computer scientist. built the leading global eHealth company, domiciled in Koblenz, up from nothing and has continued to lead and shape it since its founding. Mr. Gotthardt is also the Regional Chairman of the Economic Council of Rhineland-Palatinate, a member of the Federal Executive Board and Deputy Chairman of the Federal Commission for Health. He began his business career in the health service with the production of software for dentists. He studied Information Technology in Bonn.

CEO Compensation
  • Frank's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Frank's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the CompuGroup Medical Societas Europaea management team in years:

4.3
Average Tenure
55.5
Average Age
  • The tenure for the CompuGroup Medical Societas Europaea management team is about average.
Management Team

Frank Gotthardt

TITLE
Chairman of Management Board & CEO
COMPENSATION
€4M
AGE
69
TENURE
11 yrs

Christian Teig

TITLE
CFO & Member of Management Board
COMPENSATION
€810K
AGE
54
TENURE
10.8 yrs

Uwe Eibich

TITLE
Executive VP of Telematics & eHealth Platforms and Member of Management Board
COMPENSATION
€641K
AGE
57
TENURE
12.5 yrs

Hannes Reichl

TITLE
Member of Executive Board
COMPENSATION
€452K
TENURE
0.7 yrs

Frank Brecher

TITLE
Chief Process Officer & Member of Management Board
COMPENSATION
€558K
AGE
49
TENURE
4.3 yrs

Ralph Körfgen

TITLE
Member of Executive Board
COMPENSATION
€453K
TENURE
0.7 yrs

Benedikt Brückle

TITLE
Senior Vice President of United States & Canada
TENURE
2.5 yrs

Oliver Bruzek

TITLE
Chief Communication Officer of Political & Public Affairs

Gerhard Schütz

TITLE
Senior Vice President of ALM - Africa & Asia Pacific
TENURE
4.5 yrs

Franck Frayer

TITLE
Senior Vice President of Western European Region
TENURE
2.5 yrs
Board of Directors Tenure

Average tenure of the CompuGroup Medical Societas Europaea board of directors in years:

3.4
Average Tenure
  • The tenure for the CompuGroup Medical Societas Europaea board of directors is about average.
Board of Directors

Klaus Esser

TITLE
Chairman of Supervisory Board
TENURE
5.2 yrs

Daniel Gotthardt

TITLE
Deputy Chairman of Supervisory Board

Dierk Heimann

TITLE
Member of Medical Advisory Board

Maik Pagenkopf

TITLE
Employee Representative Supervisory Board Member
TENURE
3.4 yrs

Klaus Schrod

TITLE
Employee Representative Supervisory Board Member
TENURE
3.4 yrs

Ulrike Handel

TITLE
Supervisory Board Member
TENURE
2.2 yrs

Thomas Seifert

TITLE
Member of Supervisory Board
AGE
56
TENURE
1.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess CompuGroup Medical Societas Europaea's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. CompuGroup Medical Societas Europaea has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

CompuGroup Medical Societas Europaea (FRA:COP): What Does The Future Look Like?

After CompuGroup Medical Societas Europaea's (FRA:COP) recent earnings announcement in March 2019, the consensus outlook from analysts appear bearish, as a 2.9% fall in profits is expected in the upcoming year compared with the past 5-year average growth rate of 23%. … In this article, I've outline a few earnings growth rates to give you a sense of the market sentiment for CompuGroup Medical Societas Europaea in the longer term. … See our latest analysis for CompuGroup Medical Societas Europaea What can we expect from CompuGroup Medical Societas Europaea in the longer term?

Simply Wall St -

Should We Be Delighted With CompuGroup Medical Societas Europaea's (FRA:COP) ROE Of 35%?

View our latest analysis for CompuGroup Medical Societas Europaea How Do I Calculate Return On Equity? … The formula for ROE is: Return on Equity = Net Profit ÷ Shareholders' Equity Or for CompuGroup Medical Societas Europaea: 35% = €99m ÷ €280m (Based on the trailing twelve months to March 2019.) Most know that net profit is the total earnings after all expenses, but the concept of shareholders' equity is a little more complicated. … Does CompuGroup Medical Societas Europaea Have A Good Return On Equity?

Simply Wall St -

Is CompuGroup Medical Societas Europaea's (FRA:COP) 229% Share Price Increase Well Justified?

One great example is CompuGroup Medical Societas Europaea (FRA:COP) which saw its share price drive 229% higher over five years. … Over half a decade, CompuGroup Medical Societas Europaea managed to grow its earnings per share at 41% a year. … A Different Perspective We're pleased to report that CompuGroup Medical Societas Europaea shareholders have received a total shareholder return of 54% over one year.

Simply Wall St -

Should You Be Pleased About The CEO Pay At CompuGroup Medical Societas Europaea's (FRA:COP)

View our latest analysis for CompuGroup Medical Societas Europaea How Does Frank Gotthardt's Compensation Compare With Similar Sized Companies? … According to our data, CompuGroup Medical Societas Europaea has a market capitalization of €2.9b, and pays its CEO total annual compensation worth €4.2m. … We compared total CEO remuneration at CompuGroup Medical Societas Europaea with the amount paid at companies with a similar market capitalization.

Simply Wall St -

Is CompuGroup Medical Societas Europaea's (FRA:COP) High P/E Ratio A Problem For Investors?

We'll apply a basic P/E ratio analysis to CompuGroup Medical Societas Europaea's (FRA:COP), to help you decide if the stock is worth further research. … Looking at earnings over the last twelve months, CompuGroup Medical Societas Europaea has a P/E ratio of 29.63. … The formula for P/E is: Price to Earnings Ratio = Price per Share ÷ Earnings per Share (EPS) Or for CompuGroup Medical Societas Europaea: P/E of 29.63 = €59.9 ÷ €2.02 (Based on the trailing twelve months to March 2019.) Is A High P/E Ratio Good?

Simply Wall St -

What Type Of Shareholder Owns CompuGroup Medical Societas Europaea's (FRA:COP)?

Our analysis of the ownership of the company, below, shows that institutions own shares in the company. … See our latest analysis for CompuGroup Medical Societas Europaea DB:COP Ownership Summary, May 13th 2019 What Does The Institutional Ownership Tell Us About CompuGroup Medical Societas Europaea? … Insider Ownership Of CompuGroup Medical Societas Europaea While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders.

Simply Wall St -

CompuGroup Medical Societas Europaea (FRA:COP) Earns Among The Best Returns In Its Industry

Specifically, we'll consider its Return On Capital Employed (ROCE), since that will give us an insight into how efficiently the business can generate profits from the capital it requires. … What is Return On Capital Employed (ROCE)? … ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business.

Simply Wall St -

Here's Why I Think CompuGroup Medical Societas Europaea (FRA:COP) Might Deserve Your Attention Today

If, on the other hand, you like companies that have revenue, and even earn profits, then you may well be interested in CompuGroup Medical Societas Europaea (FRA:COP). … How Fast Is CompuGroup Medical Societas Europaea Growing. … The good news is that CompuGroup Medical Societas Europaea is growing revenues, and EBIT margins improved by 4.4 percentage points to 19%, over the last year.

Simply Wall St -

Is CompuGroup Medical Societas Europaea's (FRA:COP) Balance Sheet Strong Enough To Weather A Storm?

Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like CompuGroup Medical Societas Europaea (FRA:COP), with a market cap of €2.7b, are often out of the spotlight. … COP’s financial liquidity and debt position will be analysed in this article, to get an idea of whether the company can fund opportunities for strategic growth and maintain strength through economic downturns. … See our latest analysis for CompuGroup Medical Societas Europaea

Simply Wall St -

Why I Like CompuGroup Medical Societas Europaea (FRA:COP)

Today I've chosen to put the spotlight on CompuGroup Medical Societas Europaea (FRA:COP) due to its excellent fundamentals in more than one area. … Below, I've touched on some key aspects you should know on a high level

Simply Wall St -

Company Info

Description

CompuGroup Medical Societas Europaea develops and sells software and information technology services for healthcare sector worldwide. The company’s Ambulatory Information Systems segment provides practice management software and electronic medical records for office-based physicians, dentists, medical care centers, and physician's networks. This segment offers integrated software solutions for customers to manage, analyze, and use medical data; organize business operations; and generate invoices. Its Pharmacy Information Systems segment provides integrated clinical, administrative, and financial software applications for retail pharmacies. This segment also offers in-store and online merchandising programs. The company’s Hospital Information Systems segment provides clinical and administrative solutions for the inpatient sector. This segment serves acute hospitals; rehabilitation centers; and social services, including multi-site hospital networks and regional care organizations. Its Health Connectivity Services segment provides solutions that enable pharmaceutical companies to provide information to healthcare providers through software interfaces. This segment also offers clinical decision support systems, and drugs and therapy databases for healthcare providers; and solutions for personal health records, consumer portals, and mobile applications, as well as collects and mediates clinical data for market studies, clinical trials, etc. It serves pharmaceutical companies, health insurance companies, and other healthcare IT companies and consumers. The company was formerly known as CompuGroup Medical Aktiengesellschaft and changed its name to CompuGroup Medical Societas Europaea in February 2016. CompuGroup Medical Societas Europaea was founded in 1979 and is headquartered in Koblenz, Germany.

Details
Name: CompuGroup Medical Societas Europaea
COP
Exchange: DB
Founded: 1979
€3,493,660,572
48,828,240
Website: http://www.cgm.com
Address: CompuGroup Medical Societas Europaea
Maria Trost 21,
Koblenz,
Rhineland-Palatinate, 56070,
Germany
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
DB COP Common Shares Deutsche Boerse AG DE EUR 09. Jul 1996
OTCPK CMPV.F Common Shares Pink Sheets LLC US USD 09. Jul 1996
XTRA COP Common Shares XETRA Trading Platform DE EUR 09. Jul 1996
LSE 0MSD Common Shares London Stock Exchange GB EUR 09. Jul 1996
SWX COMPG Common Shares SIX Swiss Exchange CH CHF 09. Jul 1996
WBAG COP Common Shares Wiener Boerse AG AT EUR 09. Jul 1996
BMV COP1 N Common Shares Bolsa Mexicana de Valores MX MXN 09. Jul 1996
BATS-CHIXE COPD Common Shares BATS 'Chi-X Europe' GB EUR 09. Jul 1996
Number of employees
Current staff
Staff numbers
5,000
CompuGroup Medical Societas Europaea employees.
Industry
Health Care Technology
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/19 20:39
End of day share price update: 2019/07/19 00:00
Last estimates confirmation: 2019/07/09
Last earnings filing: 2019/05/06
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.